The PACO Project: A Clinical Study of a PAtient COach Program in Vulnerable Lung Cancer Patients (PACO)
Primary Purpose
Lung Cancer, Social Inequality
Status
Unknown status
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Patient coach
Standard care
Sponsored by
About this trial
This is an interventional supportive care trial for Lung Cancer
Eligibility Criteria
Inclusion Criteria:
- Diagnosed with non-small cell lung cancer or small cell lung cancer
- Referred for further treatment at the oncology ward OR
- Must either 1) Live alone (irrespective of education) or 2) Have no formal education beyond secondary school, or 3) Have one or more comorbidities, or 4) a performance status of 1-2, or 5) be more than 65 years old at time of inclusion.
Exclusion Criteria:
- Dementia
- Being institutionalized
- No proficiency of Danish
Sites / Locations
- Department of Oncology, Herlev HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Patient coach
Standard treatment
Arm Description
Standard care and patient coach. 5 face-to-face sessions of approximately 1-2 hours duration and 3 phone calls from inclusion to one month after end of first line treatment. Deviations from this schedule might depend on the treatment modules and on the wishes and needs of the patient. Several patients will continue directly into palliative care and the coach will thus support this transition.
Standard care.
Outcomes
Primary Outcome Measures
Receipt of first-line treatment according to clinical guidelines reported as a binary variable (yes/no)
Optimal first line treatment will be defined according to TNM status and performance status and categorized receipt of first-line treatment as binary variable (yes/no).
Secondary Outcome Measures
Differences between groups in overall quality of life using the generic EORTC QLQ-C30 questionnaire (overall quality of life and functioning levels) and the lung cancer specific questionnaire QLQ-LC13 (symptoms)
Differences between groups in patient knowledge, skill, and confidence for self-management as assessed by the Patient Activation Measure (PAM) questionnaire
Differences between groups in patients beliefs in the ability to deal efficiently with a wide range of stressors as assessed by the General Self-Efficacy Scale questionnaire
Participation in self-management plans regarding smoking cessation reported as binary variable (yes/no) as assessed by a study specific questionnaire and medical records
Differences between groups in depression and anxiety as assessed by the Hospital Anxiety and Depression Scale (HADS)
Full Information
NCT ID
NCT02686775
First Posted
January 21, 2016
Last Updated
February 15, 2016
Sponsor
Danish Cancer Society
Collaborators
University of Copenhagen
1. Study Identification
Unique Protocol Identification Number
NCT02686775
Brief Title
The PACO Project: A Clinical Study of a PAtient COach Program in Vulnerable Lung Cancer Patients
Acronym
PACO
Official Title
The PACO Project: A Randomized Clinical Study of a PAtient COach Program in Vulnerable Lung Cancer Patients
Study Type
Interventional
2. Study Status
Record Verification Date
February 2016
Overall Recruitment Status
Unknown status
Study Start Date
January 2016 (undefined)
Primary Completion Date
October 2018 (Anticipated)
Study Completion Date
October 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Danish Cancer Society
Collaborators
University of Copenhagen
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The randomized trial evaluates whether assigning a patient coach to vulnerable lung cancer patients will empower these patients to participate in the treatment decision process, help patients navigate the health care system while undergoing treatment and adhere to cancer treatment and to recommendations for supportive care. Half of the participants will receive standard care and be offered a patient coach while the other half will receive standard care.
Detailed Description
Having short education or living without a partner negatively influences lung cancer survival and low social position has been associated with higher risk of advanced stage of the lung cancer at diagnosis. Disparities exists in both curative and palliative intended treatment, even adjusted for performance status and comorbidity. Differences in stage, treatment and comorbidity at diagnosis explain most of the social inequality in lung cancer survival. Age disparities in favor of younger lung cancer patients has also been found in several studies showing that older patients do not receive the most optimal treatment although age by itself do not worsen efficacy or tolerance to combined induction and definitive treatment, radiation therapy or concurrent chemoradiation. Taken together these findings indicate that in order to reduce social inequality in lung cancer survival not only early detection should be improved but also efforts to ensure optimal treatment among lung cancer patients of low social position are needed. Survival observed in the most advantaged group of lung cancer patients should set the target for what is achievable for all lung cancer patients in Denmark.
In the present intervention the investigators bring navigation together with activation as a longitudinal intervention by assigning a patient coach to vulnerable lung cancer patients while undergoing treatment. The patient coach function will address patient barrier factors, provider factors and organizational factors through providing social support, practical assistance and linking with health personnel, which are the three main principles guiding the coach intervention. The intervention will target specific phases in the treatment trajectory, which include challenges to compliance: into treatment, maintaining treatment and finalizing treatment. The investigators will use patient coaches who are volunteers with health education to provide a support function that is affiliated to the patient. The investigators believe that assistance with navigating the system, communication with health staff and social support across care transitions will help patients to obtain best possible care Primary aim: optimal treatment depending on stage, histology and performance status Secondary aims: quality of life and symptoms, participation in self-management plans as smoking cessation, physical activity, dietary changes, and short-term survival.
The investigators expect that compared to the usual care group the intervention group will initiate and adhere more to optimal treatment according to stage and performance status. Further, compared to the usual care group the intervention group will report better quality of life, less symptoms related to disease and treatment, higher level of adherence to recommendations for smoking, diet and exercise and better survival.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer, Social Inequality
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
306 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Patient coach
Arm Type
Experimental
Arm Description
Standard care and patient coach. 5 face-to-face sessions of approximately 1-2 hours duration and 3 phone calls from inclusion to one month after end of first line treatment. Deviations from this schedule might depend on the treatment modules and on the wishes and needs of the patient. Several patients will continue directly into palliative care and the coach will thus support this transition.
Arm Title
Standard treatment
Arm Type
Active Comparator
Arm Description
Standard care.
Intervention Type
Behavioral
Intervention Name(s)
Patient coach
Intervention Type
Behavioral
Intervention Name(s)
Standard care
Primary Outcome Measure Information:
Title
Receipt of first-line treatment according to clinical guidelines reported as a binary variable (yes/no)
Description
Optimal first line treatment will be defined according to TNM status and performance status and categorized receipt of first-line treatment as binary variable (yes/no).
Time Frame
20 weeks
Secondary Outcome Measure Information:
Title
Differences between groups in overall quality of life using the generic EORTC QLQ-C30 questionnaire (overall quality of life and functioning levels) and the lung cancer specific questionnaire QLQ-LC13 (symptoms)
Time Frame
Then questionnaire will be distributed 3 times: 1) At treatment start (inclusion and baseline assessment), 2) end of treatment, approx. 20- 24 weeks after start of treatment (FU1) 3) one month after end of first line treatment (FU2)
Title
Differences between groups in patient knowledge, skill, and confidence for self-management as assessed by the Patient Activation Measure (PAM) questionnaire
Time Frame
The questionnaire will be distributed 3 times: At treatment start (inclusion and baseline assessment), 2) end of treatment, approx. 20- 24 weeks after start of treatment (FU1) 3) one month after end of first line treatment (FU2)
Title
Differences between groups in patients beliefs in the ability to deal efficiently with a wide range of stressors as assessed by the General Self-Efficacy Scale questionnaire
Time Frame
The questionnaire will be distributed 3 times: At treatment start (inclusion and baseline assessment), 2) end of treatment, approx. 20- 24 weeks after start of treatment (FU1) 3) one month after end of first line treatment (FU2)
Title
Participation in self-management plans regarding smoking cessation reported as binary variable (yes/no) as assessed by a study specific questionnaire and medical records
Time Frame
The outcome will be assessed at FU2 (one month after end of first line treatment)
Title
Differences between groups in depression and anxiety as assessed by the Hospital Anxiety and Depression Scale (HADS)
Time Frame
The questionnaire will be distributed 3 times: At treatment start (inclusion and baseline assessment), 2) end of treatment, approx. 20- 24 weeks after start of treatment (FU1) 3) one month after end of first line treatment (FU2)
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed with non-small cell lung cancer or small cell lung cancer
Referred for further treatment at the oncology ward OR
Must either 1) Live alone (irrespective of education) or 2) Have no formal education beyond secondary school, or 3) Have one or more comorbidities, or 4) a performance status of 1-2, or 5) be more than 65 years old at time of inclusion.
Exclusion Criteria:
Dementia
Being institutionalized
No proficiency of Danish
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Trille Kjaer, Postdoc
Phone
+4535257608
Email
trille@cancer.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Susanne O Dalton, Senior researcher
Email
sanne@cancer.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susanne O Dalton, Senior researcher
Organizational Affiliation
Danish Cancer Society Research Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Oncology, Herlev Hospital
City
Herlev
ZIP/Postal Code
2730
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anders Mellemgaard, MD, PhD
12. IPD Sharing Statement
Learn more about this trial
The PACO Project: A Clinical Study of a PAtient COach Program in Vulnerable Lung Cancer Patients
We'll reach out to this number within 24 hrs